Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.
Seguchi M, Aytekin A, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Waksman R, Garcia-Garcia HM, Joner M. Seguchi M, et al. Among authors: van der schaaf rj. EuroIntervention. 2024 Sep 16;20(18):e1173-e1183. doi: 10.4244/EIJ-D-24-00055. EuroIntervention. 2024. PMID: 39279514 Free article.
Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry.
Verheye S, Wlodarczak A, Montorsi P, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, Aminian A, van der Schaaf RJ, Nuruddin AA, Lee MKY. Verheye S, et al. Among authors: van der schaaf rj. EuroIntervention. 2020 Feb 7;15(15):e1383-e1386. doi: 10.4244/EIJ-D-18-01058. EuroIntervention. 2020. PMID: 30666963 Free article. No abstract available.
Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth G, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Garcia-Garcia HM, Waksman R. Haude M, et al. Among authors: van der schaaf rj. EClinicalMedicine. 2023 Apr 17;59:101940. doi: 10.1016/j.eclinm.2023.101940. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37113674 Free PMC article.
A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Garcia HM, Waksman R. Haude M, et al. Among authors: van der schaaf rj. EuroIntervention. 2023 Aug 7;19(5):e414-e422. doi: 10.4244/EIJ-D-23-00326. EuroIntervention. 2023. PMID: 37334655 Free PMC article. Clinical Trial.
Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.
Garcia-Garcia HM, Waksman R, Melaku GD, Garg M, Beyene S, Wlodarczak A, Kerai A, Levine MB, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Haude M. Garcia-Garcia HM, et al. Among authors: van der schaaf rj. Eur Heart J Cardiovasc Imaging. 2024 Mar 27;25(4):491-497. doi: 10.1093/ehjci/jead299. Eur Heart J Cardiovasc Imaging. 2024. PMID: 37936296 Clinical Trial.
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Van den Branden BJ, et al. Among authors: van der schaaf rj. EuroIntervention. 2013 Nov;9(7):841-53. doi: 10.4244/EIJV9I7A138. EuroIntervention. 2013. PMID: 23628457 Free article.
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Teeuwen K, Van den Branden BJ, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Teeuwen K, et al. Among authors: van den branden bj, van der schaaf rj. EuroIntervention. 2015 Mar;10(11):1272-5. doi: 10.4244/EIJY14M08_07. EuroIntervention. 2015. PMID: 25136884 Free article. Clinical Trial.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: van der schaaf rj. EuroIntervention. 2022 Mar 18;17(16):1340-1347. doi: 10.4244/EIJ-D-21-00419. EuroIntervention. 2022. PMID: 34483094 Free PMC article. Clinical Trial.
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. Serruys PW, et al. Among authors: van der schaaf rj. Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14. Lancet. 2015. PMID: 25230593 Clinical Trial.
Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.
Kraak RP, Kajita AH, Garcia-Garcia HM, Henriques JPS, Piek JJ, Arkenbout EK, van der Schaaf RJ, Tijssen JGP, de Winter RJ, Wykrzykowska JJ. Kraak RP, et al. Among authors: van der schaaf rj. Catheter Cardiovasc Interv. 2018 Aug 1;92(2):E106-E114. doi: 10.1002/ccd.27475. Epub 2018 Jan 14. Catheter Cardiovasc Interv. 2018. PMID: 29332307
109 results